Multiply Labs raises $75 million Series B led by NantWorks
Multiply Labs said on October 6, 2026 that NantWorks leads its $75 million Series B. New investors include AstraZeneca and Teradyne, but no valuation was disclosed.
Multiply Labs, a San Francisco company that builds robotic systems for biologics manufacturing, announced on October 6, 2026 that it had raised a $75 million Series B. The company's release says NantWorks leads the round and quotes Dr. Patrick Soon-Shiong as NantWorks' founder.
The release also names AstraZeneca, Lingotto, Teradyne and Strange Ventures as new investors. Returning backers include Casdin Capital, Lux Capital, Fifty Years, Ora Global and Founders Fund. The company says it has raised more than $100 million since it was founded in 2016.
What the release confirms and what it leaves out
The company's own release, distributed by Business Wire, is the main source for the round's size, lead and investor list. It is dated October 6, 2026. It gives no valuation, and the text reviewed contains no price per share or security type.
Some secondary write-ups in search results name a different lead group. Those reports were not checked against a primary document, so this article follows the company's release.
The terms a strategic lead usually brings
Strategic investors often ask for more than a share of the round. Orrick, a law firm, lists pro rata participation and anti-dilution protection as common requests. Some strategic investors also ask for a right of first refusal, which can limit a company's flexibility in an exit or make it less attractive to a competitor of the investor.
Information and board rights need their own handling. Orrick says that where an investor may compete in the same sector, a company can withhold pricing, customer-level data or roadmaps, or share them in summarised form. Board packs can be redacted for the investor's representatives.
Commercial agreements often sit alongside the equity. Orrick lists co-development, co-licensing, and supply or distribution deals, and advises keeping each contract's pricing and termination terms separate. The release does not say whether any new investor has a commercial agreement with Multiply Labs.
Reading a mixed investor list
The release does not label each investor as strategic or financial, so this article does not sort them. The list mixes new names with returning venture backers. Dr. Ileana Pirozzi, identified in the release as Lingotto Innovation and a member of the Multiply Labs board, says biologics manufacturing has not kept pace with the science.
Global Venturing reports a split among corporate investors on tying stakes to commercial deals. In its poll, 45% of responding corporate investors said 25% or less of their investments were tied to a partnership or commercial deal, while nearly 40% said more than half were. The article does not state the number of respondents, and the poll was published in 2022 and updated in 2023.
The release frames the round as a step from clinical-stage deployments toward commercial-scale production. It does not say which of these expectations, if any, apply to the new investors.
“The round's valuation has not been disclosed in the release.”
What the $75 million must prove next
The release lists three uses: expanding manufacturing capacity, accelerating the product roadmap, and growing engineering, regulatory and commercial teams. It describes the goal as moving from clinical-stage deployments to commercial-scale production. It also says the platform will expand from cell and gene therapy to antibodies, viral vectors and mRNA.
The performance figures in the release are company claims. It says its robotic clusters cut cost per dose by 74% and deliver up to 100 times the throughput of manual manufacturing. It also says the clusters work with existing instruments and processes, without a new facility. The sources reviewed do not independently verify either figure.
Parietti, the co-founder and CEO, says robotics is the only route to delivering these therapies at scale. The release gives no timeline or milestones for a next round. As of October 8, 2026, the stated priorities are capacity, product breadth and commercial-scale output.
